CCL2 and neoplasm: TPV/∆66R/m-IL-2/mCherry and TPV/∆66R/m-CCL-2/mCherry virotherapy in immune-reconstituted animals demonstrated similar trends over the course of the study, with the results from both recombinants showing less overall regression in tumor volume compared to control (Figure 2B,C).